A Retrospective Study of Dose-dense Paclitaxel and Carboplatin Plus Bevacizumab As First-line Treatment of Advanced Epithelial Ovarian Cancer

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2024 Apr 5

PMID 38576344

Authors

Hiromi Komazaki

Kazuaki Takahashi

Hiroshi Tanabe

Yuichi Shoburu

Misato Kamii

Akina Tsuda

Motoaki Saito

Kyosuke Yamada

Hirokuni Takano

Hirofumi Michimae

Aikou Okamoto

Affiliations

Soon will be listed here.

Abstract

Objective: This study compared the effectiveness, safety, and tolerability of dose-dense paclitaxel and carboplatin plus bevacizumab (ddTC+Bev) with ddTC for advanced ovarian cancer.

Methods: We retrospectively analyzed the clinical records of 134 patients who received ddTC+Bev or ddTC as first-line chemotherapy for stage III-IV ovarian cancer. Progression-free survival as primary endpoint of this study was compared using the log-rank test. Cox proportional hazards model and propensity score matching (PSM) were used to analyze prognostic factors, and the frequency of adverse events was examined using the χ² test.

Results: We categorized 134 patients in the ddTC+Bev (n=57) and ddTC (n=77) groups who started treatment at four related institutions from November 2013 to December 2017. No patients used poly (ADP-ribose) polymerase inhibitors as the first line maintenance therapy. The progression-free survival (PFS) of the ddTC+Bev group had a significantly better prognosis than that of the ddTC group (hazard ratio [HR]=0.50; 95% confidence interval [CI]=0.32-0.79; p<0.003). Multivariate analysis showed that ddTC+Bev regimen was a prognostic factor. However, intergroup comparison using PSM revealed that the PFS of the ddTC+Bev group had a nonsignificantly better prognosis than that of the ddTC group (HR=0.70; 95% CI=0.41-1.20; p=0.189). Few adverse events above G3 were noted for ddTC+Bev, which were sufficiently tolerable.

Conclusion: This study could not demonstrate that adding Bev to ddTC improves prognosis. Further studies with more cases are warranted.

References

Kehoe S, Hook J, Nankivell M, Jayson G, Kitchener H, Lopes T . Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386(9990):249-57. DOI: 10.1016/S0140-6736(14)62223-6. View

Fleming N, Coleman R, Tung C, Westin S, Hu W, Sun Y . Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017; 147(1):41-46. PMC: 5605462. DOI: 10.1016/j.ygyno.2017.07.137. View

Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D . Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374(9698):1331-8. DOI: 10.1016/S0140-6736(09)61157-0. View

Prat J . Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2013; 124(1):1-5. DOI: 10.1016/j.ijgo.2013.10.001. View

Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G . Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer. 2013; 49(18):3831-8. DOI: 10.1016/j.ejca.2013.08.002. View

Gonzalez-Martin A, Pothuri B, Vergote I, Christensen R, Graybill W, Mirza M . Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25):2391-2402. DOI: 10.1056/NEJMoa1910962. View

Chan J, Brady M, Penson R, Huang H, Birrer M, Walker J . Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016; 374(8):738-48. PMC: 5081077. DOI: 10.1056/NEJMoa1505067. View

Wallace S, Kumar A, Mc Gree M, Weaver A, Mariani A, Langstraat C . Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol. 2017; 145(1):21-26. DOI: 10.1016/j.ygyno.2017.01.029. View

Clamp A, James E, McNeish I, Dean A, Kim J, ODonnell D . Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019; 394(10214):2084-2095. PMC: 6902268. DOI: 10.1016/S0140-6736(19)32259-7. View

10.

Roett M, Evans P . Ovarian cancer: an overview. Am Fam Physician. 2009; 80(6):609-16. View

11.

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R . Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019; 381(25):2416-2428. DOI: 10.1056/NEJMoa1911361. View

12.

Giannini A, Di Dio C, Di Donato V, DOria O, Salerno M, Capalbo G . PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer. Am J Clin Oncol. 2023; 46(9):414-419. DOI: 10.1097/COC.0000000000001024. View

13.

Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83. DOI: 10.1056/NEJMoa1104390. View

14.

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

15.

Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A . Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int J Clin Oncol. 2018; 24(1):103-114. PMC: 6326987. DOI: 10.1007/s10147-018-1319-y. View

16.

Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E . Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label.... Lancet Oncol. 2013; 14(10):1020-6. DOI: 10.1016/S1470-2045(13)70363-2. View

17.

Harano K, Terauchi F, Katsumata N, Takahashi F, Yasuda M, Takakura S . Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology.... Ann Oncol. 2013; 25(1):251-7. DOI: 10.1093/annonc/mdt527. View

18.

Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M . Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26):2495-2505. DOI: 10.1056/NEJMoa1810858. View

19.

Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M . 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005; 16 Suppl 8:viii7-viii12. DOI: 10.1093/annonc/mdi961. View

20.

Zhang L, Zhou Q . Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. Eur J Pharmacol. 2018; 837:64-71. DOI: 10.1016/j.ejphar.2018.07.049. View